RECENT NEWS
The race for the next Ozempic is on
A next-gen Ozempic falls short in a drug trial — and Novo Nordisk stock plunges 20%
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
What Trump's win means, stronger Ozempic, and cars to avoid: The week's most popular stories